The Experts below are selected from a list of 210 Experts worldwide ranked by ideXlab platform
Larry T Glickman - One of the best experts on this subject based on the ideXlab platform.
-
corrigendumcorrigendum to a placebo controlled trial of two intranasal vaccines to prevent tracheobronchitis Kennel Cough in dogs entering a humane shelter prev vet med 62 2004 89 99
Preventive Veterinary Medicine, 2005Co-Authors: Charlotte H Edinboro, Michael P Ward, Larry T GlickmanAbstract:A placebo-controlled field trial was conducted to compare the effectiveness of intranasal (IN) vaccines containing Bordetella bronchiseptica and canine-parainfluenza virus, with (IN-BPA) or without (IN-BP) canine-adenovirus type 2, for prevention of Kennel Cough at a humane shelter. Dogs were examined on admission to the shelter and those without respiratory signs of disease were assigned daily, on a rotating basis, to receive one of three vaccines. We enrolled 972 healthy dogs. Dogs were monitored for up to 30 days postvaccination for Coughing and other clinical signs of respiratory disease. Thirty-three (10.7%; 95% confidence interval (CI): 7.2%, 14.2%) dogs in the IN-BP group, 36 (10.2%; CI: 7.0%, 13.4%) dogs in the IN-BPA group, and 42 (13.5%; CI: 9.7%,17.3%) dogs in the IN-P group Coughed spontaneously for 1 day within 30 days of vaccination (P = 0.37). The IN-BP and IN-BPA vaccines were 20.7 and 24.4% effective, respectively, in reducing Coughing compared with a placebo vaccine. The strongest prognostic factor for Coughing (regardless of vaccine group) was the number of days spent at the shelter, with each additional day increasing the risk of Coughing by 3% (95% CI: 1.01, 1.06). The low www.elsevier.com/locate/prevetmed Preventive Veterinary Medicine 69 (2005) 309–310
-
a placebo controlled trial of two intranasal vaccines to prevent tracheobronchitis Kennel Cough in dogs entering a humane shelter
Preventive Veterinary Medicine, 2004Co-Authors: Charlotte H Edinboro, Michael P Ward, Larry T GlickmanAbstract:Abstract A placebo-controlled field trial was conducted to compare the effectiveness of intranasal (IN) vaccines containing Bordetella bronchiseptica and canine-parainfluenza virus, with (IN-BPA) or without (IN-BP) canine-adenovirus type 2, for prevention of Kennel Cough at a humane shelter. Dogs were examined on admission to the shelter and those without respiratory signs of disease were assigned daily, on a rotating basis, to receive one of three vaccines. We enrolled 972 healthy dogs. Dogs were monitored for up to 30 days post-vaccination for Coughing and other clinical signs of respiratory disease. Thirty-three (10.7%; 95% confidence interval (CI): 7.2, 14.2) dogs in the IN-BP group, 36 (10.2%; 95% CI: 7.0, 13.4) dogs in the IN-BPA group, and 42 (13.5%; 95% CI: 9.7, 17.3) dogs in the IN-P group Coughed spontaneously for ≥1 day within 30 days of vaccination (P=0.37). The IN-BP and IN-BPA vaccines were 20.7 and 24.4% effective, respectively, in reducing Coughing compared with a placebo vaccine. The strongest prognostic factor for Coughing (regardless of vaccine group) was the number of days spent at the shelter, with each additional day increasing the risk of Coughing by 3% (95% CI: 0.5, 6.3). The low incidence of Coughing in the shelter during this study precluded observation of differences in vaccine effectiveness. No differences in vaccine-associated adverse events (Coughing, sneezing, nasal or ocular discharge) were noted during the first 3 days post-administration or thereafter.
-
a placebo controlled trial of two intranasal vaccines to prevent tracheobronchitis Kennel Cough in dogs entering a humane shelter
Preventive Veterinary Medicine, 2004Co-Authors: Charlotte H Edinboro, Michael P Ward, Larry T GlickmanAbstract:A placebo-controlled field trial was conducted to compare the effectiveness of intranasal (IN) vaccines containing Bordetella bronchiseptica and canine-parainfluenza virus, with (IN-BPA) or without (IN-BP) canine-adenovirus type 2, for prevention of Kennel Cough at a humane shelter. Dogs were examined on admission to the shelter and those without respiratory signs of disease were assigned daily, on a rotating basis, to receive one of three vaccines. We enrolled 972 healthy dogs. Dogs were monitored for up to 30 days post-vaccination for Coughing and other clinical signs of respiratory disease. Thirty-three (10.7%; 95% confidence interval (CI): 7.2%, 14.2%) dogs in the IN-BP group, 36 (10.2%; CI: 7.0%, 13.4%) [corrected] dogs in the IN-BPA group, and 42 (13.5%; CI: 9.7%, 17.3%) [corrected] dogs in the IN-P group Coughed spontaneously for > or = 1 day within 30 days of vaccination (P = 0.37). The IN-BP and IN-BPA vaccines were 20.7 and 24.4% effective, respectively, in reducing Coughing compared with a placebo vaccine. The strongest prognostic factor for Coughing (regardless of vaccine group) was the number of days spent at the shelter, with each additional day increasing the risk of Coughing by 3% (95% CI: 1.01, 1.06) [corrected] The low incidence of Coughing in the shelter during this study precluded observation of differences in vaccine effectiveness. No differences in vaccine-associated adverse events (Coughing, sneezing, nasal or ocular discharge) were noted during the first 3 days post-administration or thereafter.
Charlotte H Edinboro - One of the best experts on this subject based on the ideXlab platform.
-
corrigendumcorrigendum to a placebo controlled trial of two intranasal vaccines to prevent tracheobronchitis Kennel Cough in dogs entering a humane shelter prev vet med 62 2004 89 99
Preventive Veterinary Medicine, 2005Co-Authors: Charlotte H Edinboro, Michael P Ward, Larry T GlickmanAbstract:A placebo-controlled field trial was conducted to compare the effectiveness of intranasal (IN) vaccines containing Bordetella bronchiseptica and canine-parainfluenza virus, with (IN-BPA) or without (IN-BP) canine-adenovirus type 2, for prevention of Kennel Cough at a humane shelter. Dogs were examined on admission to the shelter and those without respiratory signs of disease were assigned daily, on a rotating basis, to receive one of three vaccines. We enrolled 972 healthy dogs. Dogs were monitored for up to 30 days postvaccination for Coughing and other clinical signs of respiratory disease. Thirty-three (10.7%; 95% confidence interval (CI): 7.2%, 14.2%) dogs in the IN-BP group, 36 (10.2%; CI: 7.0%, 13.4%) dogs in the IN-BPA group, and 42 (13.5%; CI: 9.7%,17.3%) dogs in the IN-P group Coughed spontaneously for 1 day within 30 days of vaccination (P = 0.37). The IN-BP and IN-BPA vaccines were 20.7 and 24.4% effective, respectively, in reducing Coughing compared with a placebo vaccine. The strongest prognostic factor for Coughing (regardless of vaccine group) was the number of days spent at the shelter, with each additional day increasing the risk of Coughing by 3% (95% CI: 1.01, 1.06). The low www.elsevier.com/locate/prevetmed Preventive Veterinary Medicine 69 (2005) 309–310
-
a placebo controlled trial of two intranasal vaccines to prevent tracheobronchitis Kennel Cough in dogs entering a humane shelter
Preventive Veterinary Medicine, 2004Co-Authors: Charlotte H Edinboro, Michael P Ward, Larry T GlickmanAbstract:Abstract A placebo-controlled field trial was conducted to compare the effectiveness of intranasal (IN) vaccines containing Bordetella bronchiseptica and canine-parainfluenza virus, with (IN-BPA) or without (IN-BP) canine-adenovirus type 2, for prevention of Kennel Cough at a humane shelter. Dogs were examined on admission to the shelter and those without respiratory signs of disease were assigned daily, on a rotating basis, to receive one of three vaccines. We enrolled 972 healthy dogs. Dogs were monitored for up to 30 days post-vaccination for Coughing and other clinical signs of respiratory disease. Thirty-three (10.7%; 95% confidence interval (CI): 7.2, 14.2) dogs in the IN-BP group, 36 (10.2%; 95% CI: 7.0, 13.4) dogs in the IN-BPA group, and 42 (13.5%; 95% CI: 9.7, 17.3) dogs in the IN-P group Coughed spontaneously for ≥1 day within 30 days of vaccination (P=0.37). The IN-BP and IN-BPA vaccines were 20.7 and 24.4% effective, respectively, in reducing Coughing compared with a placebo vaccine. The strongest prognostic factor for Coughing (regardless of vaccine group) was the number of days spent at the shelter, with each additional day increasing the risk of Coughing by 3% (95% CI: 0.5, 6.3). The low incidence of Coughing in the shelter during this study precluded observation of differences in vaccine effectiveness. No differences in vaccine-associated adverse events (Coughing, sneezing, nasal or ocular discharge) were noted during the first 3 days post-administration or thereafter.
-
a placebo controlled trial of two intranasal vaccines to prevent tracheobronchitis Kennel Cough in dogs entering a humane shelter
Preventive Veterinary Medicine, 2004Co-Authors: Charlotte H Edinboro, Michael P Ward, Larry T GlickmanAbstract:A placebo-controlled field trial was conducted to compare the effectiveness of intranasal (IN) vaccines containing Bordetella bronchiseptica and canine-parainfluenza virus, with (IN-BPA) or without (IN-BP) canine-adenovirus type 2, for prevention of Kennel Cough at a humane shelter. Dogs were examined on admission to the shelter and those without respiratory signs of disease were assigned daily, on a rotating basis, to receive one of three vaccines. We enrolled 972 healthy dogs. Dogs were monitored for up to 30 days post-vaccination for Coughing and other clinical signs of respiratory disease. Thirty-three (10.7%; 95% confidence interval (CI): 7.2%, 14.2%) dogs in the IN-BP group, 36 (10.2%; CI: 7.0%, 13.4%) [corrected] dogs in the IN-BPA group, and 42 (13.5%; CI: 9.7%, 17.3%) [corrected] dogs in the IN-P group Coughed spontaneously for > or = 1 day within 30 days of vaccination (P = 0.37). The IN-BP and IN-BPA vaccines were 20.7 and 24.4% effective, respectively, in reducing Coughing compared with a placebo vaccine. The strongest prognostic factor for Coughing (regardless of vaccine group) was the number of days spent at the shelter, with each additional day increasing the risk of Coughing by 3% (95% CI: 1.01, 1.06) [corrected] The low incidence of Coughing in the shelter during this study precluded observation of differences in vaccine effectiveness. No differences in vaccine-associated adverse events (Coughing, sneezing, nasal or ocular discharge) were noted during the first 3 days post-administration or thereafter.
Masami Mochizuki - One of the best experts on this subject based on the ideXlab platform.
-
Nosocomial Outbreak of Serious Canine Infectious Tracheobronchitis (Kennel Cough) Caused by Canine Herpesvirus Infection
Journal of clinical microbiology, 2010Co-Authors: Kazuo Kawakami, Ken Maeda, Yukinobu Tohya, Hiroyuki Ogawa, Ayako Imai, Emi Ohashi, Satoru Matsunaga, Takahisa Ohshima, Masami MochizukiAbstract:Canine herpesvirus (CHV; Canid herpesvirus 1) is principally a perinatal pathogen of pregnant bitches and newborn pups and secondarily a respiratory tract pathogen of older pups and dogs. Infectious disease of the canine respiratory tract frequently occurs among dogs in groups, in which it is called “ infectious tracheobronchitis” (ITB). Mortality from ITB is generally negligible, and the clinical importance of CHV as an ITB pathogen is considered to be low. The present report describes a novel ITB outbreak accompanied by death among aged dogs in an animal medical center. Most inpatient dogs had received medications that could induce immunosuppression. CHV was the only pathogen identified, and several CHV isolates were recovered in cell culture. No other viral pathogens or significant bacterial pathogens were found. Molecular and serological analyses revealed that the causative CHV isolates were from a single source but that none was a peculiar strain when the strains were compared with previous CHV strains. The virus had presumably spread among the dogs predisposed to infection in the center. The present results serve as a warning to canine clinics that, under the specific set of circumstances described, such serious CHV outbreaks may be expected wherever canine ITB occurs.
Biao He - One of the best experts on this subject based on the ideXlab platform.
-
a novel rabies vaccine based on a recombinant parainfluenza virus 5 expressing rabies virus glycoprotein
Journal of Virology, 2013Co-Authors: Zhenhai Chen, Zhen F. Fu, Ming Zhou, Guoqing Zhang, Clement W Gnanadurai, Biao HeAbstract:Untreated rabies virus (RABV) infection leads to death. Vaccine and postexposure treatment have been effective in preventing RABV infection. However, due to cost, rabies vaccination and treatment have not been widely used in developing countries. There are 55,000 human death caused by rabies annually. An efficacious and cost-effective rabies vaccine is needed. Parainfluenza virus 5 (PIV5) is thought to contribute to Kennel Cough, and Kennel Cough vaccines containing live PIV5 have been used in dogs for many years. In this work, a PIV5-vectored rabies vaccine was tested in mice. A recombinant PIV5 encoding RABV glycoprotein (G) (rPIV5-RV-G) was administered to mice via intranasal (i.n.), intramuscular (i.m.), and oral inoculation. The vaccinated mice were challenged with a 50% lethal challenge dose (LD50) of RABV challenge virus standard 24 (CVS-24) intracerebrally. A single dose of 10 6 PFU of rPIV5-RV-G was sufficient for 100% protection when administered via the i.n. route. The mice vaccinated with a single dose of 10 8 PFU of rPIV5-RV-G via the i.m. route showed very robust protection (90% to 100%). Intriguingly, the mice vaccinated orally with a single dose of 10 8 PFU of rPIV5-RV-G showed a 50% survival rate, which is comparable to the 60% survival rate among mice inoculated with an attenuated rabies vaccine strain, recombinant LBNSE. This isfirst report of an orally effective rabies vaccine candidate in animals based on PIV5 as a vector. These results indicate that rPIV5-RV-G is an excellent candidate for a new generation of recombinant rabies vaccine for humans and animals and PIV5 is a potential vector for oral vaccines.
-
Evaluating a parainfluenza virus 5-based vaccine in a host with pre-existing immunity against parainfluenza virus 5.
PLOS ONE, 2012Co-Authors: Zhenhai Chen, Gregory W Salyards, Stephen B. Harvey, Balázs Rada, Zhen F. Fu, Pei Xu, Biao HeAbstract:Parainfluenza virus 5 (PIV5), formerly known as simian virus 5 (SV5), is a paramyxovirus often referred to as canine parainfluenza virus (CPI) in the veterinary field. PIV5 is thought to be a contributing factor to Kennel Cough. Kennel Cough vaccines containing live PIV5 have been used in dogs for many decades. PIV5 is not known to cause any diseases in humans or other animals. PIV5 has been used as a vector for vaccine development for humans and animals. One critical question concerning the use of PIV5 as a vector is whether prior exposure to PIV5 would prevent the use of PIV5-based vaccines. In this work, we have examined immunogenicity of a recombinant PIV5 expressing hemagglutinin (HA) of influenza A virus subtype 3 (rPIV5-H3) in dogs that were immunized against PIV5. We found that vaccination of the dogs containing neutralizing antibodies against PIV5 with rPIV5-H3 generated immunity against influenza A virus, indicting that PIV5-based vaccine is immunogenic in dogs with prior exposure. Furthermore, we have examined exposure of PIV5 in human populations. We have detected neutralizing antibody (nAb) against PIV5 in 13 out of 45 human serum samples (about 29 percent). The nAb titers in humans were lower than that in vaccinated dogs, suggesting that nAb in humans is unlikely to prevent PIV5 from being an efficacious vector in humans.
Michael P Ward - One of the best experts on this subject based on the ideXlab platform.
-
corrigendumcorrigendum to a placebo controlled trial of two intranasal vaccines to prevent tracheobronchitis Kennel Cough in dogs entering a humane shelter prev vet med 62 2004 89 99
Preventive Veterinary Medicine, 2005Co-Authors: Charlotte H Edinboro, Michael P Ward, Larry T GlickmanAbstract:A placebo-controlled field trial was conducted to compare the effectiveness of intranasal (IN) vaccines containing Bordetella bronchiseptica and canine-parainfluenza virus, with (IN-BPA) or without (IN-BP) canine-adenovirus type 2, for prevention of Kennel Cough at a humane shelter. Dogs were examined on admission to the shelter and those without respiratory signs of disease were assigned daily, on a rotating basis, to receive one of three vaccines. We enrolled 972 healthy dogs. Dogs were monitored for up to 30 days postvaccination for Coughing and other clinical signs of respiratory disease. Thirty-three (10.7%; 95% confidence interval (CI): 7.2%, 14.2%) dogs in the IN-BP group, 36 (10.2%; CI: 7.0%, 13.4%) dogs in the IN-BPA group, and 42 (13.5%; CI: 9.7%,17.3%) dogs in the IN-P group Coughed spontaneously for 1 day within 30 days of vaccination (P = 0.37). The IN-BP and IN-BPA vaccines were 20.7 and 24.4% effective, respectively, in reducing Coughing compared with a placebo vaccine. The strongest prognostic factor for Coughing (regardless of vaccine group) was the number of days spent at the shelter, with each additional day increasing the risk of Coughing by 3% (95% CI: 1.01, 1.06). The low www.elsevier.com/locate/prevetmed Preventive Veterinary Medicine 69 (2005) 309–310
-
a placebo controlled trial of two intranasal vaccines to prevent tracheobronchitis Kennel Cough in dogs entering a humane shelter
Preventive Veterinary Medicine, 2004Co-Authors: Charlotte H Edinboro, Michael P Ward, Larry T GlickmanAbstract:Abstract A placebo-controlled field trial was conducted to compare the effectiveness of intranasal (IN) vaccines containing Bordetella bronchiseptica and canine-parainfluenza virus, with (IN-BPA) or without (IN-BP) canine-adenovirus type 2, for prevention of Kennel Cough at a humane shelter. Dogs were examined on admission to the shelter and those without respiratory signs of disease were assigned daily, on a rotating basis, to receive one of three vaccines. We enrolled 972 healthy dogs. Dogs were monitored for up to 30 days post-vaccination for Coughing and other clinical signs of respiratory disease. Thirty-three (10.7%; 95% confidence interval (CI): 7.2, 14.2) dogs in the IN-BP group, 36 (10.2%; 95% CI: 7.0, 13.4) dogs in the IN-BPA group, and 42 (13.5%; 95% CI: 9.7, 17.3) dogs in the IN-P group Coughed spontaneously for ≥1 day within 30 days of vaccination (P=0.37). The IN-BP and IN-BPA vaccines were 20.7 and 24.4% effective, respectively, in reducing Coughing compared with a placebo vaccine. The strongest prognostic factor for Coughing (regardless of vaccine group) was the number of days spent at the shelter, with each additional day increasing the risk of Coughing by 3% (95% CI: 0.5, 6.3). The low incidence of Coughing in the shelter during this study precluded observation of differences in vaccine effectiveness. No differences in vaccine-associated adverse events (Coughing, sneezing, nasal or ocular discharge) were noted during the first 3 days post-administration or thereafter.
-
a placebo controlled trial of two intranasal vaccines to prevent tracheobronchitis Kennel Cough in dogs entering a humane shelter
Preventive Veterinary Medicine, 2004Co-Authors: Charlotte H Edinboro, Michael P Ward, Larry T GlickmanAbstract:A placebo-controlled field trial was conducted to compare the effectiveness of intranasal (IN) vaccines containing Bordetella bronchiseptica and canine-parainfluenza virus, with (IN-BPA) or without (IN-BP) canine-adenovirus type 2, for prevention of Kennel Cough at a humane shelter. Dogs were examined on admission to the shelter and those without respiratory signs of disease were assigned daily, on a rotating basis, to receive one of three vaccines. We enrolled 972 healthy dogs. Dogs were monitored for up to 30 days post-vaccination for Coughing and other clinical signs of respiratory disease. Thirty-three (10.7%; 95% confidence interval (CI): 7.2%, 14.2%) dogs in the IN-BP group, 36 (10.2%; CI: 7.0%, 13.4%) [corrected] dogs in the IN-BPA group, and 42 (13.5%; CI: 9.7%, 17.3%) [corrected] dogs in the IN-P group Coughed spontaneously for > or = 1 day within 30 days of vaccination (P = 0.37). The IN-BP and IN-BPA vaccines were 20.7 and 24.4% effective, respectively, in reducing Coughing compared with a placebo vaccine. The strongest prognostic factor for Coughing (regardless of vaccine group) was the number of days spent at the shelter, with each additional day increasing the risk of Coughing by 3% (95% CI: 1.01, 1.06) [corrected] The low incidence of Coughing in the shelter during this study precluded observation of differences in vaccine effectiveness. No differences in vaccine-associated adverse events (Coughing, sneezing, nasal or ocular discharge) were noted during the first 3 days post-administration or thereafter.
